Financial health
- The company holds more cash ($45M) than total debt ($0).
- Operating income covered interest expense -61.1× in the latest year.
PLRX Financials PLIANT THERAPEUTICS, INC.
7 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $0 | $149M | — | — | -$129M | $0 | $45M |
| 2024 | $0 | $210M | — | — | -$159M | $30M | $71M |
| 2023 | $2M | $161M | 0.0% | -11654.7% | -$117M | $10M | $63M |
| 2022 | $10M | -$123M | 0.0% | -1313.4% | -$96M | $10M | $34M |
| 2021 | $8M | -$97M | 0.0% | -1288.1% | -$77M | $0 | $52M |
| 2020 | $42M | -$42M | 0.0% | -99.6% | -$39M | — | $51M |
| 2019 | $57M | -$631000 | 0.0% | -2.2% | -$4M | — | $86M |
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | — | -$20M | — | — | -$19M | $0 | $22M |
| Dec '25 | — | -$24M | — | — | -$18M | $0 | $45M |
| Sep '25 | — | -$26M | — | — | -$21M | $30M | $94M |
| Jun '25 | — | -$43M | — | — | -$41M | $30M | $87M |
| Mar '25 | — | -$56M | — | — | -$49M | $30M | $92M |
| Dec '24 | $0 | -$50M | — | — | -$48M | $30M | $71M |
| Sep '24 | $0 | -$58M | — | — | -$33M | $30M | $80M |
| Jun '24 | $0 | -$56M | — | — | -$47M | $30M | $80M |
| Mar '24 | $0 | -$47M | — | — | -$32M | $30M | $114M |
| Dec '23 | $0 | -$41M | — | — | -$25M | $10M | $63M |
| Sep '23 | $0 | -$41M | — | — | -$36M | $10M | $58M |
| Jun '23 | $248000 | -$41M | 0.0% | -19083.9% | -$25M | $10M | $55M |
| Mar '23 | $1M | -$38M | 0.0% | -3160.3% | -$30M | $10M | $103M |
| Dec '22 | $2M | -$35M | 0.0% | -1903.3% | -$31M | $10M | $34M |
| Sep '22 | $1M | -$31M | 0.0% | -2155.7% | -$19M | $10M | $45M |
| Jun '22 | $5M | -$30M | 0.0% | -594.1% | -$25M | $10M | $25M |
| Mar '22 | $1M | -$28M | 0.0% | -2258.7% | -$21M | — | $33M |
| Dec '21 | $2M | -$25M | 0.0% | -1230.6% | -$20M | $0 | $52M |
| Sep '21 | $2M | -$27M | 0.0% | -1684.0% | -$23M | — | $45M |
| Jun '21 | $2M | -$23M | 0.0% | -1280.3% | -$20M | — | $35M |
Valuation over time
How the market has priced PLRX against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-earnings ratio has fallen from 6.9× (Jan '24) to 1.0× (Feb '25).
- The price-to-sales ratio has risen from 170.0× (Mar '23) to 541.2× (Nov '24).
P/E
P/S
Frequently asked questions
Is PLRX growing its revenue and profit?
See the revenue and net-income charts above for PLIANT THERAPEUTICS, INC.'s multi-year trend.
How much debt does PLRX have?
As of FY2025, PLIANT THERAPEUTICS, INC. reported $0 of total debt against $45M of cash; operating income covered interest expense -61.1×.
What is PLRX's profit margin?
In FY2025, gross margin was —, operating margin —, and net margin —.
What is PLRX's P/E ratio?
As of Jun '26, PLIANT THERAPEUTICS, INC. traded at a price-to-earnings ratio of about 1.0× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.